Target intelligence / Profile preview

Large intestine microbiota (None established; sometimes referred to as "gut microbiota" or "intestinal microbiota," but no standard abbreviation specific to the large intestine.)

Target
None established; sometimes referred to as "gut microbiota" or "intestinal microbiota," but no standard abbreviation specific to the large intestine.
Molecular classification
Other (complex microbial community/ecosystem), Not classified under traditional categories like "receptor," "enzyme," etc.
01

Overview

The **large intestine microbiota**, also known as colonic or gut microbiota when referring specifically to this region, comprises trillions of microorganisms—including bacteria (~1000+ species), archaea, viruses/phages/fungi—that inhabit the human colon. This diverse ecosystem plays essential roles in digestion by fermenting otherwise indigestible dietary fibers into short-chain fatty acids that nourish colonocytes and influence systemic metabolism. It synthesizes vitamins unavailable from diet alone; regulates local/systemic immunity; protects against pathogen overgrowth; maintains mucosal barrier integrity; interacts bidirectionally with other organs including via neuroimmune pathways (“gut-brain axis”). Disruption or imbalance (“dysbiosis”) has been linked to numerous diseases ranging from metabolic syndrome/obesity/type II diabetes/inflammatory bowel disease/neuropsychiatric conditions/cancer/cardiovascular risks. Therapeutic strategies focus on restoring healthy balance through diet modification/prebiotic supplementation/probiotic administration/fecal transplantation rather than targeting any one molecule within this system directly.[1][3][4]

Other names
Gut microbiotaIntestinal microbiotaColonic microbiotaLarge bowel flora (historical/less common)Microflora of the gut (outdated)
02

Mechanism of action

For interventions:\n - Modulation/restoration/correction of dysbiotic communities by introducing beneficial microbes/providing substrates for their growth/providing competitive exclusion against pathogens/influencing metabolite production such as SCFAs/regulating immune signaling pathways/gut-brain axis modulation through metabolites/neuroactive compounds produced by microbes[2].

03

Biological functions

Digestion and fermentation of dietary fibers and complex carbohydratesProduction of short-chain fatty acids (SCFAs)Synthesis of certain vitamins (B1, B9/folate, B12, K)Regulation and development of immune system responsesProtection against pathogenic organisms ("colonization resistance")Maintenance and strengthening of gut barrier integrity
04

Disease associations

Obesity/metabolic syndrome/type 2 diabetesInflammatory bowel diseaseGastrointestinal infectionsNeuropsychiatric disorders via the gut-brain axis (e.g., depression, anxiety)Cancer risk modulationCardiovascular disease risk factorsMany chronic diseases are associated with altered gut microbial communities (“dysbiosis”)
05

Safety considerations

Risk from introducing live bacteria via probiotics/FMT—potential infection/immunocompromised host issues/allergic reactions/transmission unknown pathogens.Unpredictable effects due to inter-individual variability/compositional complexity.Long-term consequences poorly understood; off-target effects possible when altering ecosystem balance.Regulatory challenges regarding classification/safety testing/effectiveness standards for live biotherapeutics/prebiotics/FMTs.
06

Interacting drugs

Probiotics (*Lactobacillus*, *Bifidobacterium*, *Clostridium butyricum*, etc.)

3 more in the full profile.

07

Biomarkers

Diversity/richness indices from metagenomic sequencing (“alpha diversity,” “beta diversity”)Relative abundance shifts in key taxa/species/groups associated with health/disease statesLevels/patterns of SCFA production/metabolites detected in stool/blood samples

Beyond the preview

Go deeper on Large intestine microbiota (None established; sometimes referred to as "gut microbiota" or "intestinal microbiota," but no standard abbreviation specific to the large intestine.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Large intestine microbiota (None established; sometimes referred to as "gut microbiota" or "intestinal microbiota," but no standard abbreviation specific to the large intestine.).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call